{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:21:29Z","timestamp":1763018489800},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00115-022-01295-1","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T09:06:23Z","timestamp":1651827983000},"page":"549-556","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetisch basierte Therapien bei spinaler Muskelatrophie"],"prefix":"10.1007","volume":"93","author":[{"given":"T.","family":"Hagenacker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","volume":"6","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy\u00a0SA, Kolb\u00a0SJ, Lowes\u00a0L et al (2019) AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a\u00a0Prospective Natural History Cohort. J\u00a0Neuromuscul Dis 6:307\u2013317","journal-title":"J Neuromuscul Dis"},{"key":"1295_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000164","author":"WD Arnold","year":"2021","unstructured":"Arnold WD, Severyn S, Zhao S et\u00a0al (2021) Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. Bmj Neurol Open. https:\/\/doi.org\/10.1136\/bmjno-2021-000164","journal-title":"Bmj Neurol Open"},{"key":"1295_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.812063","author":"S Brakemeier","year":"2021","unstructured":"Brakemeier S, Stolte B, Thimm A et al (2021) Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen. Brain Sci. https:\/\/doi.org\/10.3389\/fneur.2021.812063","journal-title":"Brain Sci"},{"key":"1295_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand\u00a0D, Mohr\u00a0F, Mcmillan\u00a0H et al (2021) Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J\u00a0Hepatol 74:560\u2013566","journal-title":"J Hepatol"},{"key":"1295_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419887616","author":"I Cordts","year":"2020","unstructured":"Cordts\u00a0I, Lingor\u00a0P, Friedrich\u00a0B et\u00a0al (2020) Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286419887616","journal-title":"Ther Adv Neurol Disord"},{"key":"1295_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras\u00a0BT, Masson\u00a0R, Mazurkiewicz-Beldzinska\u00a0M et al (2021) Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. N\u00a0Engl J Med 385:427\u2013435","journal-title":"N Engl J Med"},{"key":"1295_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel\u00a0RS, Mercuri\u00a0E, Darras\u00a0BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N\u00a0Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"1295_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker\u00a0T, Wurster\u00a0CD, Gunther\u00a0R et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a\u00a0non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317\u2013325","journal-title":"Lancet Neurol"},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3389\/fneur.2019.01166","volume":"10","author":"K Kizina","year":"2019","unstructured":"Kizina\u00a0K, Stolte\u00a0B, Totzeck\u00a0A et al (2019) Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy. Front Neurol 10:1166","journal-title":"Front Neurol"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre\u00a0S, Burglen\u00a0L, Reboullet\u00a0S et al (1995) Identification and characterization of a\u00a0spinal muscular atrophy-determining gene. Cell 80:155\u2013165","journal-title":"Cell"},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre\u00a0S, Burlet\u00a0P, Liu\u00a0Q et\u00a0al (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16:265\u2013269","journal-title":"Nat Genet"},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri\u00a0E, Darras\u00a0BT, Chiriboga\u00a0CA et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N\u00a0Engl J Med 378:625\u2013635","journal-title":"N Engl J Med"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri\u00a0E, Deconinck\u00a0N, Mazzone\u00a0ES et al (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a\u00a0phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21:42\u201352","journal-title":"Lancet Neurol"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat\u00a0TL, Davies\u00a0KE (1992) International SMA consortium meeting. (26\u201328 June 1992, Bonn, Germany). Neuromuscul Disord 2:423\u2013428","journal-title":"Neuromuscul Disord"},{"key":"1295_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00234-019-02189-x","volume":"61","author":"D Oldenburg","year":"2019","unstructured":"Oldenburg\u00a0D, Guberina\u00a0N, Stolte\u00a0B et al (2019) Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy. Neuroradiology 61:565\u2013574","journal-title":"Neuroradiology"},{"key":"1295_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea\u00a0GE, Krober\u00a0S, Mcwhorter\u00a0ML et\u00a0al (2008) Plastin 3 is a\u00a0protective modifier of autosomal recessive spinal muscular atrophy. Science 320:524\u2013527","journal-title":"Science"},{"key":"1295_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418803246","author":"B Stolte","year":"2018","unstructured":"Stolte\u00a0B, Totzeck\u00a0A, Kizina\u00a0K et\u00a0al (2018) Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286418803246","journal-title":"Ther Adv Neurol Disord"},{"key":"1295_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ene.14586","volume":"28","author":"D Veiga-Canuto","year":"2021","unstructured":"Veiga-Canuto\u00a0D, Cifrian-Perez\u00a0M, Pitarch-Castellano\u00a0I et al (2021) Ultrasound-guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients. Eur J Neurol 28:676\u2013680","journal-title":"Eur J Neurol"},{"key":"1295_CR19","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190416","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S et al (2019) Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3\u2014A Prospective Observational Study. J\u00a0Neuromuscul Dis. https:\/\/doi.org\/10.3233\/JND-190416","journal-title":"Dis"},{"key":"1295_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","volume":"109","author":"CJJ Yeo","year":"2020","unstructured":"Yeo\u00a0CJJ, Darras\u00a0BT (2020) Overturning the Paradigm of Spinal Muscular Atrophy as Just a\u00a0Motor Neuron Disease. Pediatr Neurol 109:12\u201319","journal-title":"Pediatr Neurol"},{"key":"1295_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13023-021-01903-4","volume":"16","author":"J Zhang","year":"2021","unstructured":"Zhang\u00a0J, Cui\u00a0X, Chen\u00a0S et al (2021) Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study. Orphanet J Rare Dis 16:274","journal-title":"Orphanet J Rare Dis"},{"key":"1295_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","volume":"91","author":"A Ziegler","year":"2020","unstructured":"Ziegler\u00a0A, Wilichowski\u00a0E, Schara\u00a0U et al (2020) Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : consensus paper of the German representatives of the society for pediatric neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German society for muscular diseases (DGM). Nervenarzt 91:518\u2013529","journal-title":"Nervenarzt"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-022-01295-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T14:05:23Z","timestamp":1655301923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-022-01295-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1007\/s00115-022-01295-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"7 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Hagenacker, U.\u00a0Schara-Schmidt und C.\u00a0Kleinschnitz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}